Friday, Oct 16 2020 | Time 02:40 Hrs(IST)
image
  • ‘Udta MP’: Drugs, booze, cash seized as voting day draws nigh
  • Maratha organisation activists demonstrate for their various demands in front of Maha Minister's residence in Nanded
  • WHO Study Shows Remdesivir Has Little Effect in Reducing COVID-19 Mortality – Reports
  • Permission given for export of alcohol-based sanitizers
  • Flyover in Thane named after ex-President Kalam
  • Hooch tragedy: Cops suspended, Addl CS to probe matter
  • Provide adequate beds with essential medical facilities in hospitals: minister
  • US Democratic VP candidate Harris' travel halted over coronavirus concern
  • HP Min lays foundation stone for Majheena Sankhai Yojana project
  • UN peacekeeper killed in northeast Mali: MINUSMA
  • Israeli Parliament Approves Normalization Agreement With UAE – Reports
  • France Records 30,621 New Coronavirus Cases, New One-Day High
WorldPosted at: Oct 16 2020 1:48AM


WHO Study Shows Remdesivir Has Little Effect in Reducing COVID-19 Mortality – Reports

MOSCOW, Oct 15 (Sputnik) The antiviral drug remdesivir, which has been touted as a treatment for COVID-19, appears to have no substantial effect in reducing patient mortality, according to a fresh World Health Organization (WHO) study seen by the Financial Times newspaper on Thursday.
The newspaper said that it had seen a copy of the results from the WHO's Solidarity trial that studied the effects of using remdesivir and three other drugs to treat COVID-19.
The results appeared to show that all four drugs had little effect in reducing patient mortality, the newspaper cited the WHO as saying.
"These remdesivir, hydroxychloroquine, lopinavir and interferon regimens appeared to have little effect on in-hospital mortality," the study said, as quoted by the newspaper.
The study, which the WHO admitted has yet to be subject to peer review, also found that the four treatments had little effect on reducing the time patients were required to spend in hospital.
Remdesivir, which is produced by US pharmaceutical firm Gilead Sciences under the brand name Veklury, was initially developed to treat Ebola and has received partial approval for use in treating COVID-19 patients in the United States and the European Union.
Following US President Donald Trump's positive test for COVID-19, medical professionals said that he would undergo a five-day course of remdesivir. Since then, the president has said that he has achieved immunity from the disease and is in good health.
SPUTNIK GK 0146
Tags: #WHO Study Shows Remdesivir Has Little Effect in Reducing COVID-19 Mortality – Reports
More News

Germany reports 6638 new cases of coronavirus

15 Oct 2020 | 4:56 PM

Berlin, Oct 15 (UNI) Germany reported 6,638 fresh cases of COVID-19, taking the overall tally to 3,41,223, the Robert Koch Institute (RKI) announced on Thursday.

see more..
Kyrgyz President Sooronbai Jeenbekov resigns

Kyrgyz President Sooronbai Jeenbekov resigns

15 Oct 2020 | 4:51 PM

Bishkek, Oct 15 (UNI) Kyrgyz President Sooronbai Jeenbekov has decided to resign, his press service reported on Thursday.

see more..
Bangladesh records 1600 more COVID-19 cases, 15 deaths

Bangladesh records 1600 more COVID-19 cases, 15 deaths

15 Oct 2020 | 4:31 PM

Dhaka, Oct 15 (UNI) Bangladesh on Thursday recorded 1600 more cases of the novel coronavirus, bringing the total to 3,84,559.

see more..

Pakistan sees 'Unmistakable Signs' of COVID-19 resurgence

15 Oct 2020 | 4:25 PM

Islamabad, Oct 15 (UNI) Pakistan Planning Minister and head of COVID-19 response center Asad Umar on Thursday said that the death toll per day from the coronavirus had reached its highest point in over two months and the occurrence rate among the population was on the rise, pointing to the resurgence of the disease.

see more..
B'desh is key partner in Indo-Pacific Strategy: US Deputy Secretary Beigun

B'desh is key partner in Indo-Pacific Strategy: US Deputy Secretary Beigun

15 Oct 2020 | 4:19 PM

Dhaka, Oct 15 (UNI) Visiting US Deputy Secretary of State Stephen Beigun said his country considers Bangladesh as an important partner in Indo-Pacific oceanic region.
We are eager to further expand the cooperation in establishing free and open Indo-Pacific. Bangladesh will remain in centre in their activities, he said.
The US official told this while exchanging views with journalists here on Thursday after holding a discussion with Bangladesh Foreign Minister AK Abdul Momen.
Of the second day of his Dhaka tour, Stephen Beigun held a two-hour long meeting with Momen at State Guest House Padma.
When asked to comment on what was discussed with the Bangladesh Foreign Minister, Stephen, who attended the joint press briefing, did not say it clearly.
Washington is requesting Bangladesh to join its strategic initiative Indo-Pacific Strategy (IPS).

see more..
image